Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer.

被引：0
|
作者：
Fiascarelli, Alessio [1 ]
Merlino, Giuseppe [1 ]
Capano, Stefania [1 ]
Bressan, Alessandro [1 ]
Bigioni, Mario [1 ]
Pellacani, Andrea [2 ]
Binaschi, Monica [1 ]
Salerno, Massimiliano [1 ]
机构：
[1] Menarini Ric, Pomezia, Italy
[2] Menarini Ric, Florence, Italy
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1376
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation
    Damodaran, Senthil
    Murthy, Rashmi K.
    Nusrat, Maliha
    Saigal, Babita
    Trager, Samantha C.
    Tripathy, Debu
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2021, 81 (04)
  • [32] Exon 9 and exon 20 mutations in PIK3CA confer resistance to HER2 inhibitors in HER2-overexpressing breast cancer cells.
    Rexer, B. N.
    Chakrabarty, A.
    Rinehart, C.
    Chang, J.
    Engelman, J.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (02) : 266S - 267S
  • [33] Trastuzumab Response in Iraqi Women with Her2 Positive Breast Cancer: The Role of PIK3CA Oncogene Mutations at E542k and E545k
    Hammadi, Alyaa H.
    Ali, Shatha H.
    MEDICINA BALEAR, 2024, 39 (02):
  • [34] LAPATINIB IN BREAST CANCER - THE PREDICTIVE SIGNIFICANCE OF HER1 (EGFR), HER2, PTEN AND PIK3CA GENES AND LAPATINIB PLASMA LEVEL ASSESSMENT
    Bouchalova, Katerina
    Cizkova, Magdalena
    Cwiertka, Karel
    Trojanec, Radek
    Friedecky, David
    Hajduch, Marian
    BIOMEDICAL PAPERS-OLOMOUC, 2010, 154 (04): : 281 - 288
  • [35] B-PRECISE-01 Study: A phase lb trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.
    Piccart-Gebhart, Martine J.
    Aftimos, Philippe Georges
    Duhoux, Francois P.
    Wildiers, Hans
    Isambert, Nicolas
    Campone, Mario
    Tosi, Diego
    Varga, Andrea I.
    Boni, Valentina
    Doger, Bernard
    Garcia Corbacho, Javier
    Jimenez-Rodriguez, Begona
    Ruiz Borrego, Manuel
    Saura, Cristina
    Arkenau, Hendrik-Tobias
    Wardley, Andrew M.
    Troconiz, Inaki F.
    Binaschi, Monica
    Simonelli, Cecilia
    Pellacani, Andrea Ugo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+PIK3CA-mutated metastatic breast cancer.
    Gawryletz, Chelsea D.
    Dougherty-Gray, Colleen
    Datko, Farrah Mikhail
    Loch, Michelle Marie
    Sharifi, Marina
    Gopalakrishnan, Ragisha
    Kabos, Peter
    Borges, Virginia F.
    Shagisultanova, Elena
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Targeting PI3K and mTOR with BEZ235, a dual inhibitor, is efficacious in trastuzumab refractory and HER2+/PIK3CA-mutated breast cancer models
    Williams, Casey
    Sun, Yuliang
    Carlson, Jennifer
    Leyland-Jones, Brian
    Dey, Nandini
    De, Pradip
    CANCER RESEARCH, 2014, 74 (19)
  • [38] Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
    Kataoka, Y.
    Mukohara, T.
    Shimada, H.
    Saijo, N.
    Hirai, M.
    Minami, H.
    ANNALS OF ONCOLOGY, 2010, 21 (02) : 255 - 262
  • [39] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Xuhong, Juncheng
    Luo, Tao
    Ge, Jia
    Liu, Feng
    Lan, Yang
    Chen, Qingqiu
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Liang, Yan
    Wang, Minghao
    Hu, Ying
    Zhang, Yi
    Bian, Xiuwu
    Qi, Xiaowei
    Jiang, Jun
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 121 - 129
  • [40] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Qiyun Shi
    Juncheng Xuhong
    Tao Luo
    Jia Ge
    Feng Liu
    Yang Lan
    Qingqiu Chen
    Peng Tang
    Linjun Fan
    Li Chen
    Yan Liang
    Minghao Wang
    Ying Hu
    Yi Zhang
    Xiuwu Bian
    Xiaowei Qi
    Jun Jiang
    British Journal of Cancer, 2023, 128 : 121 - 129
12345